Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated and Comprehensive Loss (Unaudited)

v3.21.2
Condensed Consolidated and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Revenue from awards and licenses $ 97,323 $ 1,230,621 $ 881,705 $ 3,279,026
Operating expenses:        
Research and development 8,695,641 27,522,989 30,681,684 82,156,926
General and administrative 5,277,090 7,681,573 16,190,684 23,120,020
Total operating expenses 13,972,731 35,204,562 46,872,368 105,276,946
Operating loss (13,875,408) (33,973,941) (45,990,663) (101,997,920)
Other income (expense), net:        
Other income (expense), net 12,033,031 (4,972) 11,790,328 4,005
Interest income (expense), net (391,867) (454,319) (1,439,587) (348,654)
Change in fair value of derivative liability 472,143 (211,000) 670,143 (211,000)
Foreign currency exchange gain (loss), net (414,048) (251,117) (409,914) (103,903)
Other income (expense), net 11,699,259 (921,408) 10,610,970 (659,552)
Net loss $ (2,176,149) $ (34,895,349) $ (35,379,693) $ (102,657,472)
Net loss per share, basic and diluted $ (0.02) $ (0.43) $ (0.29) $ (1.37)
Weighted average number of common shares outstanding, basic and diluted 125,209,985 81,879,119 122,234,847 75,037,418
Comprehensive loss:        
Net loss $ (2,176,149) $ (34,895,349) $ (35,379,693) $ (102,657,472)
Other comprehensive income (loss):        
Unrealized gain (loss) on marketable debt securities (3,513) (8,967)
Total other comprehensive income (loss) (3,513) (8,967)
Total comprehensive loss $ (2,179,662) $ (34,895,349) $ (35,388,660) $ (102,657,472)